Cantor Fitzgerald Comments on Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mesoblast in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will earn ($0.70) per share for the year. The consensus estimate for Mesoblast’s current full-year earnings is ($0.72) per share.

MESO has been the topic of a number of other reports. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler increased their price target on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Trading Up 1.4 %

Shares of NASDAQ:MESO opened at $18.27 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The company’s fifty day moving average is $14.81 and its 200-day moving average is $10.18. Mesoblast has a 52 week low of $1.75 and a 52 week high of $22.00.

Institutional Investors Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MESO. XTX Topco Ltd bought a new stake in shares of Mesoblast during the second quarter valued at approximately $103,000. Marshall Wace LLP acquired a new position in Mesoblast during the 2nd quarter worth $562,000. Lazari Capital Management Inc. boosted its position in Mesoblast by 6.6% in the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after buying an additional 3,300 shares during the last quarter. Perkins Coie Trust Co increased its stake in shares of Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after buying an additional 1,500 shares during the period. Finally, Creative Planning bought a new stake in shares of Mesoblast during the third quarter worth $147,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.